Fig. 3

OX1R activation mediated a further reduction in IPSCs through OX1R in the presence of naloxone. a Sample traces of eIPSCs at a holding potential of − 70 mV during bath application of naloxone, orexin-A and SB, respectively, without washout. b Evoked IPSCs amplitude decreased significantly (*P < 0.05) in the presence of naloxone (1 µM), this effect were more decreased significantly (***P < 0.001) in the presence of orexin-A (100 nM). SB-334867 (3 µM, SB) reversed the suppressive effect of orexin-A (100 nM) on eIPSCs amplitude (repeated measures ANOVA followed by Student–Newman–Keuls test, *P < 0.05, n = 8). c Sample traces of sIPSCs recorded during baseline and bath application of naloxone, orexin-A and SB, respectively, without washout. d Left, spontaneous IPSCs frequency decreased significantly (*P < 0.05) in the presence of naloxone (1 µM). This effect was more decreased significantly (***P < 0.001) in the presence of orexin-A (100 nM) (repeated measure ANOVA followed by Student–Newman–Keuls test, n = 8). This effect on sIPSCs frequency is reversed by SB-334867 (3 µM) treatment (repeated measure ANOVA followed by Student–Newman–Keuls test, *P < 0.05, n = 8). Right, cumulative probability plots of sIPSCs inter-event interval compared to baseline and bath application of naloxone, orexin-A and SB, respectively. e Left, sIPSCs amplitudes were not significantly different in baseline and bath application of naloxone, orexin-A and SB, respectively. Right, cumulative probability plots of sIPSCs amplitude during baseline and bath application of naloxone, orexin-A and SB, respectively